DAIICHI SANKYO EUROPE GmbH announce SEVIKARŪ a new fixed dose combination treatment for essential hypertension
13.11.08 - 07:02 ... source : Daiichi Sankyo
... Munich, Germany (12th November 2008), DAIICHI SANKYO EUROPE GmbH announces today that its German affiliate received marketing approval for SEVIKARŪ a new fixed dose combination treatment for essential hypertension, a condition that significantly contributes to the estimated annual € 192 billion healthcare cost of cardiovascular disease in Europe(1). GERMANY, the European headquarter of DAIICHI SANKYO, is the latest country in Europe to grant marketing approval for SEVIKARŪ Approvals have been obtained over a very short time period in The Netherlands, Spain, France, United Kingdom and Belgium, with further approvals imminently anticipated in other key European markets, highlighting the importance of this new medication. SEVIKAR offers significant value through clinically significant control of blood pressure combined with cost leadership position in class, allow ...» Next (HTML)
Similar news
93% | 17.10.08 - 11:31 ... source : Lilly
... Network/ -- In response to recent media speculation regarding the status of the prasugrel new drug application (NDA), Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) reiterated today that they continue to have discussions with ...
92% | 17.10.08 - 10:15 ... source : Daiichi Sankyo
... response to recent media speculation regarding the status of the prasugrel new drug application (NDA), Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) reiterated today that they continue to have discussions with the FDA regarding ...
86% | 11.11.08 - 06:32 ... source : Daiichi Sankyo
... Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE: 4568) today announced that they have entered into two agreements that form the basis of a strategic relationship for the development and discovery of novel oncology therapeutics. ArQule and Daiichi Sankyo ...
86% | 07.11.08 - 14:27 ... source : Daiichi Sankyo
... (TSE: 4568.JP) ("Daiichi Sankyo") and Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") today announced the successful closure of their transformational deal with the execution of the final transfer of the remaining equity shares of the Singh family, in Ranbaxy. Pursuant to ...
85% | 31.10.08 - 12:24 ... source : Daiichi Sankyo
... announced that the dissolution of its subsidiaries Laboratoire Daiichi Sanofi-aventis (hereinafter LDS) and Sanofi-aventis Daiichi Pharmaceutical (hereinafter SDC) have been approved at the board of directors meeting held today. The impact of this dissolution on the earnings of DAIICHI SANKYO ...
